Neffy Is Coming to Canadian Pharmacies: Everything You Need to Know About the First Needle-Free Epinephrine

If someone in your family has a severe allergy — to food, insect stings, or medication — the way you carry emergency epinephrine in Canada is about to change.

On April 15, 2026, Health Canada approved Neffy (epinephrine nasal spray 2 mg), the first needle-free emergency epinephrine treatment in Canadian history. It's expected to be available at pharmacies across Canada in summer 2026.

As a pharmacist, this is one of the most clinically significant approvals I've seen in years — not because epinephrine is new, but because how it's delivered changes everything about whether people actually use it in time.

What Is Neffy?

Neffy is a nasal spray that delivers a single 2 mg dose of epinephrine — the same medication used in EpiPen auto-injectors — without a needle. You insert the tip into one nostril and press the plunger. That's the entire process.

It's manufactured by ARS Pharmaceuticals and distributed in Canada by ALK Canada. Health Canada approved it for emergency treatment of anaphylaxis in adults and children weighing 30 kg (approximately 66 lbs) or more.

This makes Neffy the second epinephrine device available in Canada. Until this approval, the EpiPen auto-injector — first introduced in the 1970s — was the only Health Canada-approved option.

Why This Matters More Than It Might Seem

The problem with epinephrine auto-injectors has never been the medication. It's the needle.

Research consistently shows that roughly half of Canadians living with severe allergies don't carry their prescribed epinephrine device consistently, and approximately half don't administer it when they need to during an allergic emergency. The reasons? Needle fear. Uncertainty about correct technique. Hesitation in a high-stress moment. Children who resist injections.

The consequences of delayed epinephrine in anaphylaxis are severe. Epinephrine is most effective in the first minutes of a reaction. Every minute of delay after that increases the risk of a serious outcome. People who freeze, hesitate, or avoid using an auto-injector because of the needle aren't making an irrational decision — but the outcome can be fatal.

A nasal spray removes that barrier entirely. There's no needle to expose. No injection technique to execute correctly under panic. No physical resistance from a child. You press it into a nostril. The medication absorbs rapidly through the nasal mucosa.

As one Canadian allergist put it when the approval was announced: the hope is that people will be more ready to use it in emergencies rather than delaying.

How Neffy Compares to EpiPen

Here's a practical comparison for families trying to understand their options:

| Feature | Neffy (nasal spray) | EpiPen (auto-injector) |

|---|---|---|

| Delivery method | Nasal spray — no needle | Intramuscular injection |

| Dose available in Canada | 2 mg (≥30 kg) | 0.3 mg adult / 0.15 mg junior |

| Shelf life | 30 months from manufacture | ~18 months |

| Temperature tolerance | Withstands up to 50°C; can be frozen (thaw 1 hour before use) | Sensitive to extreme heat and freezing |

| Storage requirements | No special requirements | Keep at room temperature; avoid freezing |

| Size | Pocket-sized | Larger auto-injector device |

| Availability in Canada | Expected summer 2026 | Currently available |

| Cost/coverage | Under review by Canada's Drug Agency | Covered by most provincial formularies |

Both devices deliver epinephrine. The clinical question of which is more effective in a real emergency is still being studied, but early data from the US — where Neffy has been available since 2024 — supports its effectiveness. Canadian allergists have welcomed the approval as a meaningful addition to available options.

Important: Neffy does not replace the EpiPen in every situation. If someone has nasal congestion, a nosebleed, or significant nasal obstruction, absorption may be affected. Families with severe allergy histories should discuss with their pharmacist or allergist which device — or combination of devices — is most appropriate for their situation.

Who Is It For?

Neffy 2 mg is approved for:

Who it is NOT yet approved for in Canada:

Children weighing between 15 kg and 30 kg (approximately 33–66 lbs). A lower-dose 1 mg formulation for this weight group is already approved in the United States, and ARS Pharmaceuticals has indicated it plans to file for Health Canada approval for the 1 mg dose by summer 2026. Until that approval is granted, children under 30 kg in Canada should continue using a junior EpiPen or equivalent.

What About Coverage?

This is the critical practical question — and the honest answer right now is: we don't know yet.

ALK Canada has submitted Neffy to Canada's Drug Agency (CDA) and Quebec's INESSS for formulary review, which is the first step toward provincial drug plan coverage. That review process takes time. When Neffy becomes available on pharmacy shelves in summer 2026, it may initially be available only at private pay prices until provincial formularies make coverage decisions.

We will update this post as coverage information becomes available for BC PharmaCare specifically. If you want to be notified when Neffy is available at Pill4Me and have pricing information ready for you, call us at 604-705-3644 or register your interest through our patient portal.

What Should You Do Right Now?

If you or a family member currently carries an EpiPen:

Nothing changes immediately. EpiPen remains fully available and effective. When Neffy becomes available in summer 2026, talk to your pharmacist about whether switching or carrying both makes sense for your specific situation. Your allergy history, comfort with each device, and insurance coverage all factor into that decision.

If you have a known severe allergy and don't currently carry epinephrine:

This is the conversation to have with your pharmacist or physician now — before Neffy's arrival. The approval of a needle-free option may make consistent carrying more realistic for you. Call us or come in and we'll walk through your options.

If your child has a severe allergy:

Discuss the weight threshold with your pharmacist. If your child weighs 30 kg or more, Neffy will be an option this summer. If they're under 30 kg, they'll need to wait for the 1 mg Health Canada approval, expected later in 2026.

If you want to be first in line when Neffy arrives:

Register at neffy.ca for availability updates directly from ALK Canada. We'll also announce availability at Pill4Me through our patient portal and social media channels when we have confirmed stock.

A Note on EpiPen Shortages

One reason many allergy advocates have welcomed this approval strongly is supply security. In 2018, Canada experienced significant EpiPen shortages that left many families without access to emergency epinephrine for months. Having a second approved device from a different manufacturer means that a supply disruption affecting one product doesn't leave the entire Canadian allergy community without options.

This is a meaningful public health benefit that goes beyond any individual patient's device preference.

The Bottom Line

Neffy is coming to Canadian pharmacy shelves this summer. It's the most significant change in anaphylaxis management in over 35 years. For the millions of Canadians living with severe allergies — and for the families and caregivers supporting them — it represents a genuinely meaningful new option.

It doesn't make EpiPen obsolete. It doesn't work for everyone. The coverage situation is still unresolved. But for people who have delayed or avoided using epinephrine because of needle fear, a nasal spray that delivers the same medication may be the difference between using it and not using it.

And in anaphylaxis, using it on time is everything.

---

Questions about Neffy or your current anaphylaxis prescription?

📍 Pill4Me Pharmacy · 5625 Promontory Rd Unit 101, Chilliwack BC

📞 604-705-3644

🌐 pill4.me/portal

Hours: Monday to Friday, 9 AM – 5 PM

*This article is for informational purposes and does not replace advice from your allergist, physician, or pharmacist. Always follow your anaphylaxis action plan in an emergency.*